GlassScriptPhysician profile
Waldemar Nowak
NPI 1619256534
$1,197.75
in general payments reported to CMS, 2019-2025
13 companies · $94.16 in 2025
The $94.16 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $239 · 2021: $49.48 · 2022: $15.19 · 2023: $66.83 · 2024: $17.92 · 2025: $94.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $341.78 | 2019-2021 | |
| Eisai INC. | $311.89 | 2019 | |
| Livanova USA, INC. | $175.76 | 2019 | |
| Sunovion Pharmaceuticals INC. | $89.70 | 2019-2020 | |
| Lilly USA, LLC | $62.83 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Celgene Corporation | $45.55 | 2022-2023 | Zeposia |
| Novartis Pharmaceuticals Corporation | $36.73 | 2019 | |
| Greenwich Biosciences, INC. | $30.03 | 2019 | |
| Argenx US, INC. | $24.03 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $23.06 | 2025 | Austedo Xr |
| Pfizer INC. | $20.71 | 2023 | |
| Phadia US INC. | $17.92 | 2024 | Immunocap |
| Abbvie INC. | $17.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waldemar Nowak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.